BRL-203 / BRL Medicine - LARVOL DELTA

The world's first, Biogen Biotech's non-viral targeted integration PD1-CAR-T therapy for lupus erythematosus has been approved for clinical trials in China [Google translation] (vbdata.cn) - "Shanghai Bangyao Biotechnology....announced that its clinical trial application (IND) for 'non-viral PD1-targeted integration CAR-T cell injection targeting CD19' (pipeline code: BRL-203), developed based on its non-viral site-specific integration CAR-T platform with independent intellectual property rights, has been officially approved by the Center for Drug Evaluation (CDE) of the China National Drug Administration."

New trial • Systemic Lupus Erythematosus